Orthocell Ltd (ASX: OCC) shares are outperforming the market on Tuesday.
The ASX All Ords stock is currently up 10% to $1.21.
This follows the regenerative medicine company announcing a major new application for its flagship nerve repair device, Remplir.
ASX All Ords stock jumps on exciting news
According to the release, Australian urologists have begun using its Remplir product in nerve-sparing robotic-assisted radical prostatectomies (RARP). This is a common treatment for prostate cancer.
The company revealed that the device has already been used in about 40 surgical cases aimed at improving recovery of erectile function and urinary continence after surgery.
This marks a significant development because prostate surgery often results in damage to the neurovascular bundle surrounding the prostate. And despite advances such as robotic surgery, up to 80% of men experience erectile dysfunction and up to 35% suffer urinary incontinence after the procedure.
But by wrapping and protecting nerves during surgery, Remplir may reduce those risks.
Expanding a global market opportunity
The release reveals that the ASX All Ords stock believes the use of Remplir in prostate surgery has the potential to expand its total addressable market significantly.
It is already rolling out Remplir in the US, a market it estimates to be already worth US$1.6 billion, and early adoption is building momentum. Plans are also underway to accelerate launches in Canada and Europe.
With around 12,000 robotic prostate surgeries performed annually in Australia alone, the new application adds to Orthocell's existing presence in orthopaedics and reconstructive surgery.
And with approximately $27 million in cash and no debt, Orthocell believes it is well-positioned to drive rapid product adoption to deliver a step change in revenue in FY 2026.
The ASX All Ords stock's chief executive, Paul Anderson, believes the development underscores the versatility of the company's technology. He commented:
The use of Remplir in nerve-sparing robotic-assisted radical prostatectomy highlights the product's versatility and superior performance in the protection and reconstruction of damaged peripheral nerves. Surgeons across multiple specialties—including orthopaedics, plastic and reconstructive surgery, and now urology—are increasingly adopting Remplir to simplify procedures, minimise scarring, and improve functional recovery.
This represents a significant step forward in Remplir's organic expansion into broader peripheral nerve repair applications and has the potential to substantially increase the device's global total addressable market.
